Evidence map›Paper›PMID 26099008›Full record

ArticleThe American journal of surgical pathology2015

Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.

Robertson Mackenzie, Aline Talhouk, Sima Eshragh, Sherman Lau, Daphne Cheung, Christine Chow, Nhu Le, Linda S Cook, Nafisa Wilkinson, Jacqueline McDermott and 8 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of surgical pathology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Morphological and molecular characterization of epithelial ovarian cancer: SEOM-SEAP consensus guidelines for biomarker integration in clinical practice.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Guideline
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Molecular Trajectory ofFrontiers in oncology · 2020
    Review
  13. Ovarian Carcinoma Histotype: Strengths and Limitations of Integrating Morphology With Immunohistochemical Predictions.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2019
    Article
  14. Article
  15. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2019
    Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Robertson Mackenzie*Department of Molecular Oncology §Cancer Control Research, BC Cancer Agency Cancer Research Centre †Department of Pathology and Laboratory Medicine ‡Genetic Pathology Evaluation Centre, Anatomical Pathology at the Vancouver General Hospital ‡‡Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, University of British Columbia, Vancouver, BC, Canada ∥Department of Internal Medicine, University of New Mexico, Albuquerque, NM §§Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB ¶The Leeds Teaching Hospitals NHS Trust, Leeds #Barts Health NHS Trust, London, United Kingdom **Institut für Pathologie, Referenzzentrum für Gynäkopathologie, Mannheim ††Gynecologic Oncology Center, Kiel ∥∥Department of Gynecology and Obstetrics, Tuebingen University Women's Hospital, Tuebingen, Germany.
Aline Talhouk
Sima Eshragh
Sherman Lau
Daphne Cheung
Christine Chow
Nhu Le
Linda S Cook
Nafisa Wilkinson
Jacqueline McDermott
Naveena Singh
Friedrich Kommoss
Jacobus Pfisterer
David G Huntsman
Martin Köbel
Stefan Kommoss
C Blake Gilks
Michael S Anglesio

Funding

Mitochondrial DNA and Ovarian Cancer Risk and SurvivalR01CA160669 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI COOK, LINDA S · 2012 to 2016
$2.2M
Canadian Institutes of Health ResearchNCI NIH HHS R01 CA160669NCI NIH HHS R01 CA160669-01A1
6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) consists of 5 major histotypes: high-grade serous carcinoma (HGSC), endometrioid carcinoma (EC), clear cell carcinoma (CCC), mucinous carcinoma (MC), and low-grade serous carcinoma (LGSC). Each can have a broad spectrum of morphologic appearances, and 1 histotype can closely mimic histopathologic features more typical of another. Historically, there has been a relatively high frequency of mixed, defined by 2 or more distinct histotypes present on the basis of routine histopathologic assessment, histotype carcinoma diagnoses (3% to 11%); however, recent immunohistochemical (IHC) studies identifying histotype-specific markers and allowing more refined histotype diagnoses suggest a much lower incidence. We reviewed hematoxylin and eosin-stained slides from 871 cases of EOC and found the frequency of mixed carcinomas to be 1.7% when modern diagnostic criteria are applied. Through international collaboration, we established a cohort totaling 22 mixed EOCs, consisting of 9 EC/CCC, 4 EC/LGSC, 3 HGSC/CCC, 2 CCC/MC, and 4 other combinations. We interrogated the molecular differences between the different components of each case using IHC, gene expression, and hotspot sequencing analyses. IHC data alone suggested that 9 of the 22 cases were not mixed tumors, as they presented a uniform immuno-phenotype throughout, and these cases most probably represent morphologic mimicry and variation within tumors of a single histotype. Synthesis of molecular data further reduces the incidence of mixed carcinomas. On the basis of these results, true mixed carcinomas with both morphologic and molecular support for the presence of >1 histotype within a given tumor represent <1% of EOCs.

Indexed as

Biomarkers, TumorAdenocarcinoma, MucinousAlbertaBiopsyBritish ColumbiaCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialDNA Mutational AnalysisEuropeFemaleGene Expression ProfilingGenetic Predisposition to DiseaseHumansImmunohistochemistryNeoplasms, Complex and MixedNeoplasms, Glandular and EpithelialBiomarkers, Tumor

Identifiers

PMID26099008
PMCPMC4604016

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.